A phase I study of the vitamin D 3 analogue ILX23-7553 administered orally to Patients with advanced solid tumors

Rajul K. Jain, Donald L. Trump, Merrill J. Egorin, Manuel Fernandez, Candace S. Johnson, Ramesk K Ramanathan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. Patients and Methods: Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. Results: Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 μg/m 2/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. Conclusions: ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.

Original languageEnglish (US)
Pages (from-to)1420-1425
Number of pages6
JournalInvestigational New Drugs
Volume29
Issue number6
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Cholecalciferol
Hypercalcemia
Vitamin D
Neoplasms
Adrenal Gland Neoplasms
Radioligand Assay
Maximum Tolerated Dose
Radioimmunoassay
Pharmacokinetics
Dogs
Growth
Pharmaceutical Preparations
Therapeutics

Keywords

  • Calcitriol
  • Cancer
  • Oncology
  • Phase I
  • Vitamin D

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

A phase I study of the vitamin D 3 analogue ILX23-7553 administered orally to Patients with advanced solid tumors. / Jain, Rajul K.; Trump, Donald L.; Egorin, Merrill J.; Fernandez, Manuel; Johnson, Candace S.; Ramanathan, Ramesk K.

In: Investigational New Drugs, Vol. 29, No. 6, 12.2011, p. 1420-1425.

Research output: Contribution to journalArticle

Jain, Rajul K. ; Trump, Donald L. ; Egorin, Merrill J. ; Fernandez, Manuel ; Johnson, Candace S. ; Ramanathan, Ramesk K. / A phase I study of the vitamin D 3 analogue ILX23-7553 administered orally to Patients with advanced solid tumors. In: Investigational New Drugs. 2011 ; Vol. 29, No. 6. pp. 1420-1425.
@article{3e8a10149f5c4cbc9aee2b7cd70dfbae,
title = "A phase I study of the vitamin D 3 analogue ILX23-7553 administered orally to Patients with advanced solid tumors",
abstract = "Purpose: ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. Patients and Methods: Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. Results: Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 μg/m 2/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. Conclusions: ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.",
keywords = "Calcitriol, Cancer, Oncology, Phase I, Vitamin D",
author = "Jain, {Rajul K.} and Trump, {Donald L.} and Egorin, {Merrill J.} and Manuel Fernandez and Johnson, {Candace S.} and Ramanathan, {Ramesk K}",
year = "2011",
month = "12",
doi = "10.1007/s10637-010-9492-5",
language = "English (US)",
volume = "29",
pages = "1420--1425",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "6",

}

TY - JOUR

T1 - A phase I study of the vitamin D 3 analogue ILX23-7553 administered orally to Patients with advanced solid tumors

AU - Jain, Rajul K.

AU - Trump, Donald L.

AU - Egorin, Merrill J.

AU - Fernandez, Manuel

AU - Johnson, Candace S.

AU - Ramanathan, Ramesk K

PY - 2011/12

Y1 - 2011/12

N2 - Purpose: ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. Patients and Methods: Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. Results: Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 μg/m 2/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. Conclusions: ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.

AB - Purpose: ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. Patients and Methods: Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. Results: Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 μg/m 2/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. Conclusions: ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.

KW - Calcitriol

KW - Cancer

KW - Oncology

KW - Phase I

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84856032626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856032626&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9492-5

DO - 10.1007/s10637-010-9492-5

M3 - Article

VL - 29

SP - 1420

EP - 1425

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 6

ER -